RICARDO
12.7.2022 01:03:08 CEST | Business Wire | Press release
As part of its mission to support the decarbonisation of the global energy sector, Ricardo, a world-class, strategic environmental and engineering consulting company, has received 3million GBP from the UK Government to design, install and operate a combined heat and power demonstrator plant with a carbon negative footprint which will showcase climate repairing technology. The plant will demonstrate the effectiveness of community scale greenhouse gas removal and clean energy using sustainably-sourced forestry waste. The funding is awarded through the Net Zero Innovation Portfolio (NZIP) under the Department of Business, Energy and Industrial Strategy (BEIS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005348/en/
Ricardo is leading the consortium delivering the demonstrator plant. The consortium combines an innovative carbon capture system developed by Ricardo with the hot air turbine technology from Bluebox Energy and pyrolysis technology from Woodtek Engineering. The quarter-sized demonstrator plant, which will be located at Holmsted Farm in West Sussex in the UK, will be commissioned and operational in 2023. It will demonstrate not only a highly innovative greenhouse gas removal technology, that in the full-size system can generate renewable heat and electricity for up to 300 local homes and businesses, but also a realistic carbon negative technology that can significantly contribute to net zero targets.
Tim Curtis, Managing Director, Ricardo Energy and Environment said: “Ricardo is a trusted advisor to governments around the world on climate change policy and the transition to clean energy, and is also well known for its mission to decarbonise the global transport and energy sectors. In partnership with Bluebox Energy and Woodtek Engineering, this project will demonstrate that our innovative and integrated carbon capture system can be used to benefit local communities, bolster the UK’s reputation as a pioneer in negative emission technologies, and provide a sustainable and commercially viable pathway to net-zero while also delivering national energy security.”
Ricardo’s project is one of several across the UK which will benefit from a share of over 54 million GBP to develop technologies that remove carbon emissions from the atmosphere. Announcing this investment, UK Government’s Energy and Climate Change Minister Greg Hands said: “This 54 million GBP government investment will help establish a greenhouse gas removal industry in the UK, which could be worth billions to our economy, bringing in private investment and supporting the creation of new green jobs.”
The technology works by taking sustainably sourced waste wood from domestic timber production and then processing it in three ways: producing biochar (a product similar to charcoal); generating heat and power; and capturing carbon dioxide from the exhaust. The technology, therefore, captures around 95% of the carbon content in the wood. It also produces commercially marketable carbon products: the biochar can be used by farmers to enrich soil and add to animal feed to reduce ruminant emissions. The industrial-grade carbon dioxide can either be used for making low-carbon concrete or in the food and drinks industry to replace carbon dioxide derived from industrial processes which rely on imported natural gas. A full-size system will remove 16,000 tonnes of carbon dioxide per year from the atmosphere.
Ricardo has been collaborating with Bluebox Energy since June 2020 to deliver innovative technologies that support the transition to a low carbon future. This project is a further boost to Ricardo’s credentials in tackling climate change and meeting national net zero targets. Ricardo is currently actively supporting clients in Europe in innovative carbon capture technologies and has advised the UK Government on the potential of bioenergy with carbon capture in the UK. Ricardo supports clients across a wide range of industries develop their industrial decarbonisation plans on the route to net zero.
Ends
About Ricardo
Ricardo plc is a world-class strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
Department for Business, Energy & Industrial Strategy
This funding has been made available from the government’s £1 billion Net Zero Innovation Portfolio , which looks to accelerate the commercialisation of low-carbon technologies and systems, through its Direct Air Capture and Greenhouse Gas Removal Innovation Competition. This competition will provide funding for developing technologies that enable the removal of greenhouse gases from the atmosphere in the UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom